Loading
A phase 1/2 trial of JMBI-001 run by Chengdu Anticancer Bioscience, Ltd., now recruiting.
Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers is a phase 1/2 interventional study registered as NCT07864701 by Chengdu Anticancer Bioscience, Ltd., with 150 participants planned, started 2026-10. Conditions recorded: Advance Solid Tumors and Lymphoma, Non-Hodgkin. Interventions recorded: JMBI-001 Tablets.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/